SEC Tracker
Get the app

Attovia Therapeutics ATTO

Attovia Therapeutics reported $0 revenue and $22.27 million net loss for Q3 2026.

Attovia Therapeutics (ATTO) filed a 10-Q with the SEC on Nov 9, 2026, 4:16 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $22.27 million for the three months ended Sep 30, 2026
  3. Diluted EPS: -$0.76 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $115.37 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Attovia Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.